Publications
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia2020 | Central Library of Charles University
- Single-agent ibrutinib in RESONATE-2TM and RESONATETM versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia2019 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)2023 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, First Faculty of Medicine
- COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group2023 | Faculty of Medicine in Hradec Králové, Central Library of Charles University, Faculty of Medicine in Pilsen
- Pulmonary damage in a patient with hairy cell leukemia - infectious involvement or hematological disease activity? Case report2023 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- Managing BTK inhibitor treatment-related adverse events in patients with chronic lymphocytic leukaemia - cardiovascular complications and bleeding2023 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Other malignancies in the history of CLL: an international multicenter study coducted by ERIC, the European Research Initiative on CLL, in HARMONY2023 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL2023 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia2023 | Faculty of Medicine in Hradec Králové
- Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia2023 | Faculty of Medicine in Hradec Králové
Loading network view...